RxDoctor Payments Data

Paramjit Takhar, MD

Family Medicine · Sacramento, CANPI 1184791048

Payments from drug & device makers

$5,574in general payments, 2019–2025

Across 288 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$699
  • AbbVie$684
  • GSK$620
  • Novo Nordisk$394
  • Boehringer Ingelheim$288
  • Novartis$243
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$1503%
  • Food & beverage$5,39497%
  • Other$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,574 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$796,536
Medicare patients
839
Services billed
8,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate411$446,427
EliquisApixaban184$222,863
JardianceEmpagliflozin175$193,188
TrulicityDulaglutide94$190,384
Breo ElliptaFluticasone/Vilanterol169$91,596
FarxigaDapagliflozin Propanediol66$87,224
XareltoRivaroxaban75$85,640
EntrestoSacubitril/Valsartan54$80,033
OzempicSemaglutide50$75,691
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog100$53,300
Advair HfaFluticasone Propion/Salmeterol116$51,533
BreynaBudesonide/Formoterol Fumarate233$46,381
TradjentaLinagliptin36$40,230
LinzessLinaclotide46$40,079
Lantus SolostarInsulin Glargine,hum.Rec.Anlog283$39,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$150$469,482434 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$288$268,117261 claims
PfizerEliquis$186$222,863184 claims
Lilly USA, LLCTrulicity$167$190,38494 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$620$152,457281 claims
AstraZenecaFarxiga, Brilinta, Lokelma$699$132,114104 claims
Novo NordiskOzempic, Rybelsus$394$107,50369 claims
Johnson & JohnsonXarelto$72$85,64075 claims
NovartisEntresto$243$80,03354 claims
AbbVieLinzess, Lumigan, Restasis$684$66,958103 claims
UCB, Inc.Briviact$27$32,15315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →